Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the trial. “Whether semaglutide could be beneficial in preventing progression of cardiometabolic disease will be evaluated in the SELECT trial,” the authors write.
Suggestion For You:
Abstract/Full Text (subscription or payment may be required) The researchers found that participants had significantly greater odds of achieving ≥10 percent, ≥15 percent, and ≥20 percent weight loss with semaglutide versus liraglutide (odds ratios, 6.3, 7.9, and 8.2, respectively). Discontinuation of treatment for any reason occurred in 13.5 percent with semaglutide and 27.6 percent with liraglutide. Gastrointestinal adverse events occurred in 84.1 percent with semaglutide and 82.7 percent with liraglutide.
The News Highlights
- Semaglutide superior to liraglutide for weight loss – Consumer Health News
- Check the latest Health news updates and information about health.